Targeted Medical Pharma Reports Fourth Quarter and Fiscal Year 2013 Financial Results

Year-Over-Year Revenue Increase of 31% and Gross Profit Increase of 60% for the year ended December 31, 2013

Los Angeles, CA, March 31, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its fourth quarter and fiscal year ended December 31, 2013.  The Company posted increased revenues, gross profit and a reduction in net loss before interest, taxes, depreciation and amortization, stock based compensation (Adjusted EBITDA*) on both a year-over-year and a quarterly basis.

Financial Overview

Year-over-Year Comparison:

Improved financial results for the year ended December 31, 2013 compared to the year ended December 31, 2012

  • Total revenue of $9.6 million, a 31% improvement from $7.3 million during the year ended December 31, 2012.
  • Total gross profit of $6.6 million, a 60% improvement from $4.1 million during the year ended December 31, 2012.
  • Adjusted EBITDA of $(2.7) million, a 41% improvement from ($4.5) million during the year ended December 31, 2012.

Sequential Comparison:

Improved financial results for the quarter ended December 31, 2013 compared to the quarter ended September 30, 2013

  • Total revenue of $2.6 million, a 20% improvement from $2.2 million during the quarter ended September 30, 2013.
  • Total gross profit of $1.9 million, a 22% improvement from $1.6 million during the quarter ended September 30, 2013.
  • Adjusted EBITDA of $0.1 million, a 112% improvement from ($1.1) million during the quarter ended September 30, 2013.

Net loss for the year ended December 31, 2013, was $9.3 million compared to a net loss of $9.6 million for the year ended December 31, 2012.  During the years ended December 31, 2013 and 2012, the Company’s net loss consisted of a significant amount of non-cash charges.  For instance, the net loss for the year ended December 31, 2013 was negatively affected by the Company’s decision to provide a valuation allowance of $7.4 million for its deferred tax assets.  If the Company had not recorded a full valuation allowance, then the Company’s net loss would have been $1.9 million.

Due to the impact of these non-cash charges on the Company’s reported net loss, the Company places greater emphasis on improvements in Adjusted EBITDA.  A reconciliation of net loss to Adjusted EBITDA is reflected in the following table:

2013 year end table

Management Comments

“The fourth quarter and year ended December 31, 2013, were decisive periods for our Company.   The implementation and growth of new business verticals coupled with improvements in operations efficiency, resulted in accelerated reimbursement rates for our products and reduced operating costs.” said William Shell, M.D., Chief Executive Officer and Chief Science Officer of Targeted Medical Pharma “I firmly believe that executing our strategic initiatives in both sales and operations continues to add value for our shareholders. The fourth quarter was our eighth consecutive quarter of revenue growth, on a year-over-year basis.  I believe that our focus on revenue growth, through accelerated payment terms, and cost containment is beginning to be reflected in our financial results, as evidenced by our overall profitability during the quarter ended December 31, 2013, of $0.5 million.  Since our revenues are, in part, dependent upon the timing of our cash receipts we are at risk of significant fluctuations in our reported results.  Despite these quarterly fluctuations, I remain confident in our ability to continue to grow our business.”

2014 Strategic Initiatives:

  • Expansion of sales and marketing efforts to increase utilization, awareness and acceptance by physicians, patients and payers with an emphasis on expansion into markets that provide near-term revenue growth opportunities;
  • Conduct additional clinical trials for current and pipeline products including a new medical food indicated for the dietary management of Autism and Autism Spectrum Disorders, as well as a post market study with the military joint command examining the efficacy of Theramine for the reduction of back pain within the active duty military;
  • Development of the Company’s direct to consumer business that includes dietary and nutritional supplements.

A copy of Targeted Medical Pharma’s annual report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission on March 31, 2014, is accessible on the Company’s website at www.tmedpharma.com and at the SEC’s website at www.sec.gov.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals.  The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking.  Forward-looking statements also include any other passages that relate to expected future events or trends that can only be evaluated by events or trends that will occur in the future.  The forward-looking statements are based on the opinions and estimates of management at the time the statements were made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements.  These risks and uncertainties include, among others, the risk of unforeseen changes in customer budgets, unanticipated loss of customers or delays in anticipated orders, the potential failure to attract new customers due to the company’s inability to competitively market its products and services, the risk of fluctuating demand for the company’s product, the potential failure to maintain desired customer relationships, costs and risks related to development of technologies.  More information about factors that could cause actual results to differ materially from those predicted in Targeted Medical Pharma’s forward-looking statements is set out in its annual report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission.  Readers are cautioned not to place undue reliance upon these forward-looking statements, which speak only as to the date of this release.  Except as required by law, Targeted Medical Pharma, undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.

*Adjusted EBITDA refers to a financial measure that is more fully defined as net loss before net interest and other income, interest expense, income taxes, depreciation and amortization, and stock based compensation.  Adjusted EBITDA is a non-GAAP financial measure which management believes reflects the Company’s ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in the Company’s business, as they exclude certain income or other expenses that are not reflective of ongoing operating results.  Adjusted EBITDA is commonly used to analyze companies on the basis of leverage and liquidity.  However, Adjusted EBITDA is not a measure determined under GAAP in the United States of America and may not be comparable to similarly titled measures reported by other companies.  Adjusted EBITDA should not be construed as a substitute for net loss or as a better measure of liquidity than cash flow from operating activities, which are determined in accordance with GAAP.  Management believes that Adjusted EBITDA is a useful measure for analyzing operating results, and uses this non-GAAP financial measure to review past results and forecast future results.

 

####

Healthcare Executive Dr. Thomas Wenkart Joins Targeted Medical Pharma’s Board of Directors

Los Angeles, March 10, 2014 –Targeted Medical Pharma, Inc. (OTCQB:TRGM) today announced that Dr. Thomas Wenkart, Chief Executive and Chairman at Macquarie Health Corporation, has joined the company’s board of directors.

A nationally respected expert in healthcare, medical and hospital administration in Australia, Dr. Wenkart established Macquarie Health Corporation in Sydney, Australia in 1976. His organization owns and operates eleven private hospitals in Australia, and is one of the nation’s leading providers of healthcare services.

Dr. Wenkart is a graduate of the Sydney University School of Medicine. In 1976, he established the Health Care Research Institute and the Wenkart Foundation which supports the Arts and Health Sciences with the credo of “community benefits in the shortest possible time.” In 2007 the Wenkart Foundation established the Wenkart Chair of Endothelium Medicine at Sydney University and the Centenary Institute.  Dr. Wenkart has a unique understanding and interest in, medical computing, electronic health records, biomedical technology, and videodermoscopy systems. In 2003, he acquired Derma Medical Systems in Austria.

“We are very pleased to have Dr. Wenkart join our company. He brings a great deal of healthcare and business experience to our board,” said Dr. William Shell, Chief Executive Officer and Chief Science Officer at Targeted Medical Pharma. “His expertise in operations and management systems will help the continued growth and execution of strategic initiatives of our company in the United States and abroad.”

Twitter: @tmedpharma

Facebook: www.facebook.com/targetedmedicalpharma

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

# # # #

Targeted Medical Pharma Launches E-Prescribe Platform for Theramine®

Improving Provider and Patient Access to Safe and Effective Pain Medications

Los Angeles, CA, March 4, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), announced today the launch of a new e-prescribing platform for the medical food, Theramine. The secure online e-prescribing portal is available to healthcare providers in the United States, interested in a clinically validated, peer reviewed, non-pharmacologic alternative to narcotic and NSAID pain medications for patients suffering from pain syndromes.

Theramine is a medical food indicated for the dietary management of pain syndromes, and has been the subject of two double-blind, randomized, multi-center trials, which compared Theramine to low dose naproxen and ibuprofen. 256 subjects participated in the two studies across 10 independent sites that were randomized for treatment to receive Theramine alone (two capsules twice daily), NSAID or a combination of both. In both studies, Theramine showed a statistically significant reduction in inflammation and improvement in low back pain than either naproxen at 250mg daily or ibuprofen at 400mg daily.

“Clinical evidence suggests that by addressing the increased amino acid requirements of pain syndromes you can significantly improve pain perception and reduce inflammation,” said William Shell M.D., CEO and Chief Science Officer at Targeted Medical Pharma. “Theramine is a very useful clinical tool for physicians interested in managing pain and inflammation without the GI or cardiovascular side effects associated with NSAIDs or the addictive potential of narcotics.”

Visit https://tmedpharma.com/secure/eprescribe for more information about e-prescribing Theramine or any other Targeted Medical Pharma products.

Twitter: @tmedpharma

Facebook: www.facebook.com/targetedmedicalpharma

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

 Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # # #

Targeted Medical Pharma Completes Promotion and Distribution Agreement for Clearwayz™

Promotion in Several Major Markets Using Direct-Response Commercials

Los Angeles, CA, February 11, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), reported today on the completion of a promotion and distribution agreement with As Seen on TV Productions, a division of East Shore Enterprises, a company which specializes in brand promotion  using Direct-Response television commercials and internet promotion for select audiences in major markets.

The non-exclusive agreement provides a platform for Clearwayz, to connect to a wider consumer base through online and television advertising. Clearwayz is a dietary supplement specially formulated to support healthy sinus, respiratory and immune function using a proprietary blend of amino acids and polyphenols.

“Clearwayz offers a natural, drug-free option to people who are struggling with sinus and respiratory problems related to the cold, flu, or allergies and are concerned about the side effects of drugs,” said William Shell, M.D. CEO and Chief Science Officer of Targeted Medical Pharma, Inc. “This agreement will introduce this unique product into a broader marketplace, helping to build a sustainable sales channel for the dietary supplement division of the Company.”

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Follow us on Twitter

Learn more on Facebook

 Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

# # # #

Targeted Medical Pharma Selected as one of the “Best Six Stocks” by Wall-Street.com

Recognizing Growth and Market Potential in the Microcap Space 

Los Angeles, January 27, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) announced today that is has been selected as one of the best six stocks in the microcap space by industry specialist Wall-Street.com, a division of Wall-Street Media Co.

“We have worked very hard to be in a position to gain this type of recognition, and it is an honor to be chosen as one of the best six stocks by the industry specialist Wall-Street.com,” said William Shell, M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc. “Many of the companies Wall-Street.com ranks in their top 15 percent stand an excellent chance of delivering immense value to their shareholders, and we intend to achieve that goal by continuing to execute our business strategy.”

About Wall-Street.com

Wall-Street.com was established in 1994 as one of the first financial websites dedicated to covering the growing microcap space. Wall-Street.com focuses on providing investors with detailed financial and industry information regarding microcap companies. Wall-Street.com was acquired by Wall-Street Media Co. in 2011.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, 48 convenience kits and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

#               #               #

Targeted Medical Pharma Announces Completion of Sales Agreement with Pacific Medical, Inc

Agreement Provides the Company with the Ability to Rapidly Expand Sales and Education Programs

Los Angeles, CA, January 10, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), reported on the completion of an independent sales agreement with Pacific Medical, Inc., a distributor of durable medical equipment in the United States who specializes in orthopedic, rehabilitation, surgery and sports medicine.

The non-exclusive agreement will allow Targeted Medical Pharma to expand medical food sales and education programs to licensed healthcare professionals in Northern California and Northern Nevada for an initial period of one year. The programs will focus on educating prescribers who are currently treating patients with sleep, pain, obesity, and cognitive disorders about safe, effective, non-narcotic medical food treatment options.

“Pacific Medical is another important new business partner of Targeted Medical Pharma, we are very pleased with the sales contract and believe that Pacific Medical’s stellar reputation for delivering quality products and education programs will help healthcare providers understand the importance of utilizing our medical food products as a first line therapy for mitigating pain and inflammation without the risks associated with narcotic pain medications,” said William Shell, M.D. CEO and Chief Science Officer of Targeted Medical Pharma, Inc. “ We believe that Pacific Medical will help enhance the quality of our sales and education program and increase our market penetration with orthopedic and sports medicine specialists.”

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

# # # #

Targeted Medical Pharma to Present at the Demy-Colton 2014 BIOTECH Showcase

Targeted Medical Pharma to Present at the Demy-Colton 2014 BIOTECH Showcase

Los Angeles, January 9, 2014 — Targeted Medical Pharma, announced that members of its executive team are scheduled to present the latest information regarding medical foods at the sixth annual Biotech Showcase™ on January 14, 2014 at 4:00 p.m. PST, at the Parc 55 Wyndham Hotel in San Francisco, CA. Management also will conduct one-on-one meetings with investors from January 13-15, 2014.

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives at one of the industry’s largest annual healthcare investor conferences. The event is expected to attract 1,700 attendees from around the world. Targeted Medical Pharma is one of 230 companies selected to present at this year’s showcase.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # # #

Targeted Medical Pharma Reports Initial Results from a Clinical Observation of Medical Foods for Children and Adults with Autistic Spectrum Disorder Symptoms

Addressing the Nutrient Deficiencies Associated with Autism Spectrum Disorders for both Children and Adults

Los Angeles, CA, December 23, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), announced additional preliminary findings from an investigator initiated clinical observation of amino acid based medical foods to address specific nutrient deficiencies in children and young adults with autism spectrum disease (ASD) symptoms.

34 subjects including 29 children and 5 young adults ages seven to twenty-one who were diagnosed with ASD or suffering from related symptoms including explosive behavior, social isolation, and mood disorder were treated with an amino acid based formulation for one to several months. The investigators reported that 33 of the subjects were initial responders and demonstrated significant improvement with regards to decreased disruptive outbursts, improved socialization, improved mood and reduction in drug dose. Patients with explosive outbursts improved an average of 83 percent compared to baseline. The five adults reported improved mood and reduction of anxiety from 50% to 90% and in one case a 100% reduction in symptoms of mania. The investigators caution that the sample for adults is small and that an additional four cases were lost to follow-up.

“The formulations used in the investigation are milligram amounts of precursors to neurotransmitters using a proprietary technology protected by several patents.” said William Shell, M.D., CEO and Chief Science Officer of Targeted Medical Pharma.  “Autism affects the way patients metabolize certain nutrients and we believe that our medical food technology is a safe and effective way to increase amino acid and neurotransmitter levels for both children and adults. A key target of the formulation is the glutamine/glutamate access which is known to be disrupted in autistic spectrum disease patients. Measurement of amino acid concentrations in plasma and cerebrospinal fluid indicate a significant alteration of amino acid concentrations demonstrating a specific need for nutritional management of the amino acid concentrations.”

“The current pharmacologic treatments available for this patient population do not address the specific nutrient deficiencies, and are associated with a host of negative side effects,” said David Silver, M.D., President and Chief Operating Officer at Targeted Medical Pharma. “The initial results from this observation show that the symptoms of Autism in children and young adults can potentially be improved by addressing the specific nutritional deficiencies of the disease. The amino acids used in the study are considered generally recognized as safe(GRAS) and no significant side effects were observed.”

A double-blind randomized placebo controlled trial will be initiated shortly.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

# # # #

Targeted Medical Pharma Senior Management Buys Stock and Converts Loans to Equity

17,780 Shares Purchased on the Open Market and $1,000,000 Loan Converted to Stock

Los Angeles, CA, December 18, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced that senior management has purchased 17,780 shares of the Company’s stock in the open market during the fourth quarter of 2013. In addition, Company CEO William Shell, M.D. also converted $1,000,000 in loans, which were made to the company in 2011 to fund production growth, into TRGM common stock.

“The purchase of shares and conversion of loans by members of senior management demonstrates our strong confidence in the company and reflects our commitment to executing our business plan and delivering shareholder value.” Said David Silver M.D., President and Chief Operating Officer at Targeted Medical Pharma. “We have worked very hard to improve revenue and manage operating costs and today’s announcement reflects our growing confidence in Targeted Medical and the medical foods sector.”

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

# # # #

Targeted Medical Pharma to Present at 6th Annual LD Micro Growth Conference

Los Angeles, December 4, 2013 – Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced that members of its executive team are scheduled to present and conduct one-on-one meetings at the LD Micro Growth Conference on December 5, 2012 at 1:30 p.m. Pacific Time. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc., is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for autistic spectrum disorders and for the oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.